Mark Gurney
机构: Tetra Discovery Partners
每年引用次数
引用次数
引用: 34,368
H-指数: 75
I10-指数 : 175
出版物: 368
BPN14770 Alleviates Cognitive Impairment and Amyloid Pathology in APP/PS1/hPDE4D Mice
Jinpeng Lyu , Ying Xu , Shichao Gao , Mark Gurney
NEUROPSYCHOPHARMACOLOGY 45 ( SUPPL 1) 330 -330
2020
BPN14770 Clinical Development for Fragile X Syndrome
Mark Gurney , Michael Tranfaglia , Patrica Cogram , Scott Reines
NEUROTHERAPEUTICS 15 ( 3) 827 -827
2018
Structural biology and molecular pharmacology of phosphodiesterase 4 (PDE4) regulation
Mark Gurney
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 248
2014
Biaryl substituted heterocycle inhibitors of lta4h for treating inflammation
Jasbir Singh , Vincent Sandanayaka , Mark Gurney , Peng Yu
2014
Structural and Pharmacological Studies of PDE4 Subtype Selective Allosteric Inhibitors
Mark Gurney
NEUROPSYCHOPHARMACOLOGY 38 S96 -S97
2013
composto, composiÇço farmacÊutica, e, uso de uma quantidade terapeuticamente eficaz de um composto
Jasbir Singh , Vicent Sandanayaka , Mark Gurney , Peng Yu
2011
Alzheimer's Disease Secretase, APP Substrates Thereof, and Uses Thereof
Mark Gurney , Michael Jerome Bienkowski
2009
Aryl sulfonamide peri-substituted bicyclics for occlusive artery disease
Jasbir Singh , Mark Gurney , Georgeta Hategan
2009
composto, uso de um composto ou um éster do mesmo, composição farmacêutica, e, método para a triagem de ligandos do receptor de prostanóide seletivos
Jasbir Singh , Mark Gurney , Georgeta Hategan
2008
PVASP as a biomarker for platelet activation: Inhibition of the EP3 receptor by the novel antiplatelet agent DG-041 prevents pVASP dephosphorylation
Maria Bjarnadottir , Olafur Magnusson , Adalheidur G Hansdottir , Gudrun V Halldorsdottir
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY 28 ( 6) E103 -E103
2008
composto, uso em um composto ou um éster, um sal farmaceuticamente aceitável ou um hidrato do mesmo, formulação farmacêutica, e, método para a triagem in vitro de ligandos de receptor de prostanóide seletivos
Nian Zhou , Jasbir Singh , Mark Gurney , Georgeta Hategan
2008
DG-051: A novel leukotriene A4 hydrolase inhibitor for the treatment of myocardial infarction and stroke
Jasbir Singh , Vincent Sandanayaka , Bjorn Mamat , Jennifer Winger
DRUGS OF THE FUTURE 32 26 -26
2007
Reduction of plaque size and 5LO, AL0X5P, and LTA4H gene expression a dyslipidemic mouse model of atherogenesis by DG-031, an inhibitor of leukotriene biosynthesis
Jon Mar Bjornsson , Einar Jorundsson , Gudmundur Sigthorsson , Thorkell Andresson
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY 27 ( 6) E60 -E60
2007
DG-041, a novel antiplatelet agent, is a potent and selective antagonist of the EP3 receptor for prostaglandin E2
Jasbir Singh , Thorkell Andresson , Jose Ramirez , Wayne Zeller
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY 27 ( 6) E80 -E80
2007
The EP3 receptor for prostaglandin E2 in peripheral arterial disease
Maria Bjarnadottir , Thorkell Andresson , Kolbeinn Gudmundsson , Mark Gurney
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY 27 ( 6) E109 -E109
2007
Biaryl substituted heterocycle inhibitors of lta4h for treating inflammation
Vincent Sandanayaka , Jasbir Singh , Mark Gurney , Bjorn Mamat
2007
MEDI 420-Design, synthesis, and SAR of novel leukotriene A4 hydrolase inhibitors containing chiral piperidine and piperazine scaffolds
Vincent Sandanayaka , Bjorn Mamat , Louis Bedell , Nikhil Bhagat
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 232
2006
MEDI 419-Discovery of indazole derivatives as potent leukotriene A4 hydrolase inhibitors
Lei Zhao , Bjorn Mamat , Rama Mishra , Guorun Halldorsdottir
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 232
2006
ENZYME CATALYSIS AND REGULATION-Bicarbonate enhances peroxidase activity of Cu, Zn-superoxide dismutase. Role of carbonate anion radical and scavenging of carbonate anion radical by metalloporphyrin
Hao Zhang , Joy Joseph , Mark Gurney , David Becker
Journal of Biological Chemistry 277 ( 2) 1013 -1020
2002
ORCA–Online Research@ Cardiff
Magdalena A Czubala , Robert H Jenkins , Mark Gurney , Leah Wallace